The combination of Annamycin and Cytarabine, referred to as “AnnAraC,” will be evaluated under the Phase 3 “MIRACLE” trial, which stands for Moleculin R/R AML AnnAraC Clinical Evaluation.

The MIRACLE trial will evaluate Annamycin in combination with Cytarabine for patients with AML who have not responded to or have relapsed after initial therapy. The study employs an adaptive ...

This early unblinding will involve 30 participants receiving the combination of annamycin and cytarabine ... gains approval for enrolment in trial of AML therapy in Ukraine" was originally ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Annamycin's approval in AML alone would bring the potential to ... in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 ...